<code id='733F95FCE2'></code><style id='733F95FCE2'></style>
    • <acronym id='733F95FCE2'></acronym>
      <center id='733F95FCE2'><center id='733F95FCE2'><tfoot id='733F95FCE2'></tfoot></center><abbr id='733F95FCE2'><dir id='733F95FCE2'><tfoot id='733F95FCE2'></tfoot><noframes id='733F95FCE2'>

    • <optgroup id='733F95FCE2'><strike id='733F95FCE2'><sup id='733F95FCE2'></sup></strike><code id='733F95FCE2'></code></optgroup>
        1. <b id='733F95FCE2'><label id='733F95FCE2'><select id='733F95FCE2'><dt id='733F95FCE2'><span id='733F95FCE2'></span></dt></select></label></b><u id='733F95FCE2'></u>
          <i id='733F95FCE2'><strike id='733F95FCE2'><tt id='733F95FCE2'><pre id='733F95FCE2'></pre></tt></strike></i>

          Home / entertainment / hotspot

          hotspot


          hotspot

          author:focus    Page View:19
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In